-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the license in model has been hot.
According to incomplete statistics, there were 11 license in transactions among domestic pharmaceutical companies in October, with a total disclosed transaction amount exceeding US$2.
2 billion, involving Huadong Pharmaceutical, Shanghai Pharmaceutical, Hansen Pharmaceutical, and China Resources Double Crane.
, Luoxin Pharmaceutical and other pharmaceutical companies
.
Among them, Hansen Pharmaceuticals and Shanghai Pharmaceuticals both completed 2 transactions in the month
.
Specifically, Hansen Pharmaceuticals announced on October 12 that the company OliXPharmaceuticals has reached an agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China
.
According to the agreement, OliXPharmaceuticals will receive a down payment of 6.
5 million U.
S.
dollars, and up to 450 million U.
S.
dollars in important milestone payments and franchise license sharing
.
It is reported that OliXPharmaceuticals will use GalNAc-asiRNA platform technology to discover lead drugs and ensure the development of drug candidates for liver-related cardiovascular, metabolic and other disease targets
.
Hansen Pharmaceuticals will have the exclusive commercial rights of these therapies in China (including Hong Kong, Macau and Taiwan), and OliXPharmaceuticals will have rights in other regions outside the region
.
On October 15th, Hansen Pharmaceuticals announced its cooperation with SilenceTherapeuticsplc.
The two parties will use SilenceTherapeuticsplc's exclusive mRNAiGOLD™ platform to jointly develop siRNA drugs targeting three targets
.
Under the agreement, Silence Therapeutics will receive an upfront payment of US$16 million and is eligible for additional development, regulatory and commercial milestone payments of up to US$1.
3 billion
.
In addition, SilenceTherapeutics will also receive royalties in the range of approximately 10% to 15% of net product sales
.
On October 9th, Shanghai Pharmaceuticals announced that its subsidiary Shanghai Xinyi and Guizhou Shengnuo have reached a cooperation agreement to obtain the exclusive commissioned production of raw materials and preparations of the new acid inhibitor X842 project in China and the industrial sales rights for all indications
.
According to the agreement, Guizhou Shengnuo will receive 690 million yuan in related payments
.
Next, the two parties will further discuss cooperation in the form of equity investment and joint development, and accelerate the development and listing of X842 and other products under research
.
It is reported that X842 is a new generation of potassium ion-competitive acid blocker (P-CAB) oral drug.
Clinical data shows that X842 may be used to treat severe esophagitis (Grade C and D), and Potential therapy for patients with poor response to PPI therapy
.
On October 28, Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharmaceutical Xinyi and KoBioLabs.
Inc.
(KoBioLabs) have reached a licensing cooperation to obtain the development of new probiotic drugs KBL697 and KBL693 projects in China (including Hong Kong, Macau and Taiwan) , Production, registration, distribution, sales, marketing, promotion and relicensing rights, including all indications of KBL697 and KBL693 as medicines, as well as the exclusive rights of KBL697 and KBL693 as food, health products, and special medical foods
.
According to the agreement, KoBioLabs can obtain related payments of US$107 million
.
It is reported that KBL697 and KBL693 are two single-strain live bacteria medicines that have entered the clinical stage and are used to treat a variety of immune system diseases.
They are expected to become one of the promising treatments for immune system diseases
.
It is worth mentioning that in addition to license in, Shanghai Pharmaceuticals also initiated a license out transaction in October
.
On October 29, Shanghai Pharmaceuticals announced that it has reached an agreement with HUYABIO to pay for the rights to manufacture, use, sell, import, develop and commercialize SPH6162 with independent intellectual property rights outside of China (including Hong Kong, Macau and Taiwan, the same below) Exclusively licensed to HUYABIO, the relevant rights and interests of SPH6162 in China are still owned by Shanghai Pharmaceuticals
.
According to the agreement, Shanghai Pharmaceuticals can obtain a transaction amount of no more than US$292.
5 million
.
It is reported that SPH6162 is an anti-tumor small molecule inhibitor independently developed by Shanghai Pharmaceuticals.
It is currently in the preclinical development stage.
International patent applications for two compounds have been submitted, and no drugs with the same target have been approved for marketing in the world
.
According to incomplete statistics, there were 11 license in transactions among domestic pharmaceutical companies in October, with a total disclosed transaction amount exceeding US$2.
2 billion, involving Huadong Pharmaceutical, Shanghai Pharmaceutical, Hansen Pharmaceutical, and China Resources Double Crane.
, Luoxin Pharmaceutical and other pharmaceutical companies
.
Among them, Hansen Pharmaceuticals and Shanghai Pharmaceuticals both completed 2 transactions in the month
.
Specifically, Hansen Pharmaceuticals announced on October 12 that the company OliXPharmaceuticals has reached an agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China
.
According to the agreement, OliXPharmaceuticals will receive a down payment of 6.
5 million U.
S.
dollars, and up to 450 million U.
S.
dollars in important milestone payments and franchise license sharing
.
It is reported that OliXPharmaceuticals will use GalNAc-asiRNA platform technology to discover lead drugs and ensure the development of drug candidates for liver-related cardiovascular, metabolic and other disease targets
.
Hansen Pharmaceuticals will have the exclusive commercial rights of these therapies in China (including Hong Kong, Macau and Taiwan), and OliXPharmaceuticals will have rights in other regions outside the region
.
On October 15th, Hansen Pharmaceuticals announced its cooperation with SilenceTherapeuticsplc.
The two parties will use SilenceTherapeuticsplc's exclusive mRNAiGOLD™ platform to jointly develop siRNA drugs targeting three targets
.
Under the agreement, Silence Therapeutics will receive an upfront payment of US$16 million and is eligible for additional development, regulatory and commercial milestone payments of up to US$1.
3 billion
.
In addition, SilenceTherapeutics will also receive royalties in the range of approximately 10% to 15% of net product sales
.
On October 9th, Shanghai Pharmaceuticals announced that its subsidiary Shanghai Xinyi and Guizhou Shengnuo have reached a cooperation agreement to obtain the exclusive commissioned production of raw materials and preparations of the new acid inhibitor X842 project in China and the industrial sales rights for all indications
.
According to the agreement, Guizhou Shengnuo will receive 690 million yuan in related payments
.
Next, the two parties will further discuss cooperation in the form of equity investment and joint development, and accelerate the development and listing of X842 and other products under research
.
It is reported that X842 is a new generation of potassium ion-competitive acid blocker (P-CAB) oral drug.
Clinical data shows that X842 may be used to treat severe esophagitis (Grade C and D), and Potential therapy for patients with poor response to PPI therapy
.
On October 28, Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharmaceutical Xinyi and KoBioLabs.
Inc.
(KoBioLabs) have reached a licensing cooperation to obtain the development of new probiotic drugs KBL697 and KBL693 projects in China (including Hong Kong, Macau and Taiwan) , Production, registration, distribution, sales, marketing, promotion and relicensing rights, including all indications of KBL697 and KBL693 as medicines, as well as the exclusive rights of KBL697 and KBL693 as food, health products, and special medical foods
.
According to the agreement, KoBioLabs can obtain related payments of US$107 million
.
It is reported that KBL697 and KBL693 are two single-strain live bacteria medicines that have entered the clinical stage and are used to treat a variety of immune system diseases.
They are expected to become one of the promising treatments for immune system diseases
.
It is worth mentioning that in addition to license in, Shanghai Pharmaceuticals also initiated a license out transaction in October
.
On October 29, Shanghai Pharmaceuticals announced that it has reached an agreement with HUYABIO to pay for the rights to manufacture, use, sell, import, develop and commercialize SPH6162 with independent intellectual property rights outside of China (including Hong Kong, Macau and Taiwan, the same below) Exclusively licensed to HUYABIO, the relevant rights and interests of SPH6162 in China are still owned by Shanghai Pharmaceuticals
.
According to the agreement, Shanghai Pharmaceuticals can obtain a transaction amount of no more than US$292.
5 million
.
It is reported that SPH6162 is an anti-tumor small molecule inhibitor independently developed by Shanghai Pharmaceuticals.
It is currently in the preclinical development stage.
International patent applications for two compounds have been submitted, and no drugs with the same target have been approved for marketing in the world
.
